InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Insider track record
CFODisclosed buys
2
Disclosed sells
0
T+90 hit rate
42%
T+90 mean return
+3.3%
Across 12 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by LINDAHL RICHARD S, Chief Financial Officer. Officer active across 1 company, notably Emergent BioSolutions Inc.. Cumulatively, 18 disclosures have been published. Split: 2 buys · 0 sell. Total volume traded: €196k. History available since 8 May 2021. The latest transaction was disclosed on 6 March 2025 (Attribution). Regulator: SEC (Form 4). All data is openly available.
Declarations18 total
146,888 shares0Common StockSEC:0001367644-25-000051:0
16,916 shares0Common StockSEC:0001367644-25-000030:0
15,000 shares0Common StockSEC:0001367644-24-000164:0
2,733 shares@ US$6.193.9% of flowCommon StockSEC:0001367644-24-000105:0
9,037 shares@ US$3.236.8% of flowCommon StockSEC:0001367644-24-000021:0
4,012 shares@ US$2.712.5% of flowCommon StockSEC:0001367644-24-000008:0
24,616 shares0Common StockSEC:0001367644-23-000122:0
6,154 shares0Common StockSEC:0001367644-23-000068:0
1,074 shares@ US$12.383.2% of flowCommon StockSEC:0001367644-23-000057:0
444 shares@ US$14.301.5% of flowCommon StockSEC:0001367644-23-000035:0
101 shares0Common StockSEC:0001367644-23-000014:0
31,417 shares0Common StockSEC:0001367644-22-000042:0
516 shares@ US$42.230.0047% mcap5.9% of flowCommon StockSEC:0001367644-22-000032:0
1,836 shares0Common StockSEC:0001367644-22-000020:0
3,000 shares@ US$37.460.024% mcap30.4% of flowCommon StockSEC:0001367644-21-000144:0
Ideal exit: 12 Aug 2022 (T+270)
3,000 shares@ US$37.460.024% mcap64.6% of flowCommon StockSEC:0001367644-21-000144
Ideal exit: 12 Aug 2022 (T+270)
1,054 shares@ US$61.6216.6% of flowCommon StockSEC:0001367644-21-000079
1,054 shares@ US$61.620.013% mcap16.6% of flowCommon StockSEC:0001367644-21-000079:0
18 of 18 declarations
About LINDAHL RICHARD S
Richard S. Lindahl is the Chief Financial Officer and EVP of Emergent BioSolutions Inc. In this role, he is responsible for the financial management of the company, including financial planning and risk management. With significant experience in the biopharmaceutical sector, he contributes to the financial strategy and growth of the company. His expertise is essential for ensuring profitability and sustainability.
